Deals Of The Week: Merck KGaA/Symphogen, Valeant/Medicis, Medivir/Novadex
Executive Summary
Achillion brought in nearly $42 million in its third large fundraising over the past 24 months, but the virology-focused biotech may become an increasingly sought acquisition target as other hepatitis C candidates face hurdles or are shelved entirely.